NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
January 27, 2004 • Volume 1 / Number 4 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Article
UPDATE (November 4, 2010)

NCI has since released results from the National Lung Screening Trial (NLST) described below. The trial compared the effects of two lung cancer screening procedures—low-dose helical computed tomography (CT) and standard chest X-ray—on lung cancer mortality and found 20 percent fewer lung cancer deaths among trial participants screened with low-dose helical CT. Read more >>

National Lung Screening Trial Reaches Goal of 50,000 Participants

The National Cancer Institute (NCI), in partnership with the American Cancer Society (ACS), has enrolled its goal of 50,000 current or former smokers in the National Lung Screening Trial (NLST). The study, launched in September 2002, was designed to determine if screening with either spiral computed tomography (CT) or chest X-ray before the appearance of symptoms of lung cancer can reduce deaths from the disease. NLST remains open at select sites to collect blood, urine, and phlegm to help doctors identify biomarkers, or tumor markers, of lung cancer.

"Reaching this goal is a tremendous first step in our efforts to learn as much as we can about lung cancer screening," said NCI Director Andrew C. von Eschenbach, M.D. "This is a critically important trial and the rapid accrual means we're quickly moving forward to obtain answers about screening. This is very encouraging."

Spiral CT uses X-rays to scan the entire chest. A computer creates images from the scan, assembling them into a three-dimensional model of the lungs. To date, no scientific evidence has shown that screening or early detection of lung cancer with either spiral CT or chest X-rays actually saves lives.

Regional ACS offices have helped NLST sites raise awareness of the trial in their communities. The American College of Radiology Imaging Network (ACRIN), a network of researchers who conduct imaging studies, and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, both funded by NCI, are conducting the trial at more than 30 sites across the country.

"The American Cancer Society is pleased to be a part of an ongoing collaboration to encourage enrollment in NLST," said Ralph B. Vance, M.D., F.A.C.P., national volunteer president of the American Cancer Society. "We are extremely proud of our ability to help contribute. We believe what we learn from NLST will lead to saving more lives from lung cancer."

NLST is a randomized, controlled study, the "gold standard" of research studies. Study participants have been randomly assigned - designated by chance - to receive either a chest X-ray or a spiral CT once a year for three years. Researchers will continue to contact participants annually to monitor their health until 2009.

"We commend NLST sites for reaching this goal in 16 short months," said NLST Project Officer John Gohagan, Ph.D., of NCI's Division of Cancer Prevention, "and now it is just as crucial for participants to return for their follow-up X-ray or scan."

"Over the coming years of this trial, NLST participants will play a key role in answering critical questions about the use of screening with chest X-ray or CT scans to lower lung cancer deaths," said ACRIN researcher and NLST Principal Investigator Denise Aberle, M.D., of the University of California, Los Angeles.

This year, lung cancer will claim an estimated 160,000 lives in this country. There are an estimated 90 million current and former smokers in the United States, most of whom could benefit from the findings of NLST.